Micrus Endovascular Initiates VISSIT Trial With Pharos Vitesse Balloon Expandable Stent Micrus Endovascular Corporation (Nasdaq:MEND) today announced it has enrolled the first patient in the Vitesse Intracranial Stent Study for Ischemic Therapy (VISSIT), an investigational device exemption (IDE) study designed to compare clinical outcomes between patients treated with the Company's Pharos™ Vitesse™ Balloon Expandable Stent and the current best medical practice.
Source: www.medicalnewstoday.comResearch Finds Internal Choices Are Weaker Than Those Dictated By The Outside World The underlying sense of being in control of our own actions is challenged by new research from UCL (University College London) which demonstrates that the choices we make internally are weak and easily overridden compared to when we are told which choice to make.
Source: www.medicalnewstoday.comMetabolite Linked To Aggressive Prostate Cancer Discovered By Researchers Researchers from the University of Michigan Comprehensive Cancer Center have identified a panel of small molecules, or metabolites, that appear to indicate aggressive prostate cancer. The finding could lead to a simple test that would help doctors determine which prostate cancers are slow-growing and which require immediate, aggressive treatment. Results of the study appear in the Feb.
Source: www.medicalnewstoday.comEthex Corporation Product Recall Nationwide voluntary recall of products at wholesale and retail level because they may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing Practices.
Source: www.fda.govOxygen Biotherapeutics, Inc. Announces Plans For Additional Oxycyte(R) Phase II Clinical Trials Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced plans to file a Phase II, dose escalation, clinical trial protocol in Switzerland for use of Oxycyte® in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier. The announcement came in a presentation today by Chris J.
Source: www.medicalnewstoday.comDangerous Printer Particles Identified The identity and origin of tiny, potentially hazardous particles emitted from common laser printers have been revealed by a new study at Queensland University of Technology.
Source: www.medicalnewstoday.comTopical Anesthetics Patients, healthcare professionals, and caregivers alerted to serious hazards of using skin numbing products for relieving pain from mammography and other medical tests and conditions, especially when applied to a large area of skin or when the area of application is covered.
Source: www.fda.gov
# posted by Network @ 10:02 AM
